β 2 -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the β 2 -adrenoceptor with possible implications for the treatment of asthma.

MLA

De Pascali, Francesco, et al. “β 2 -Adrenoceptor Agonist Profiling Reveals Biased Signalling Phenotypes for the β 2 -Adrenoceptor with Possible Implications for the Treatment of Asthma.” British Journal of Pharmacology, vol. 179, no. 19, Oct. 2022, pp. 4692–708. EBSCOhost, https://doi.org/10.1111/bph.15900.

APA

De Pascali, F., Ippolito, M., Wolfe, E., Komolov, K. E., Hopfinger, N., Lemenze, D., Kim, N., Armen, R. S., An, S. S., Scott, C. P., & Benovic, J. L. (2022). β 2 -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the β 2 -adrenoceptor with possible implications for the treatment of asthma. British Journal of Pharmacology, 179(19), 4692–4708. https://doi.org/10.1111/bph.15900

Chicago

De Pascali, Francesco, Michael Ippolito, Emily Wolfe, Konstantin E Komolov, Nathan Hopfinger, Douglas Lemenze, Nicholas Kim, et al. 2022. “β 2 -Adrenoceptor Agonist Profiling Reveals Biased Signalling Phenotypes for the β 2 -Adrenoceptor with Possible Implications for the Treatment of Asthma.” British Journal of Pharmacology 179 (19): 4692–4708. doi:10.1111/bph.15900.